Dianthus raises ~$270M in public offering of common stock and pre-funded warrants

Dianthus Therapeutics, Inc. /DE/

Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.
Underwriters exercised in full option for additional 1,140,000 shares.
Net proceeds expected to be approximately $270 million after discounts and expenses.
Offering priced Sept 9, 2025; closing expected Sept 11, 2025.
Pre-funded warrants exercisable at any time; beneficial ownership cap of 4.99%-19.99%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.